Maricely Reina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maricely Reina has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
David Andrade
Fundación Universitaria Ciencias de la Salud, Bogotá, Colômbia
6 shared publicationsRodolfo Torres
Renal Transplant Service, Clínica Universitaria Colombia Keralty, Bogota, Colombia
6 shared publicationsCarlos Rosselli
Department of Nephrology Fundación Universitaria de Ciencias de la Salud (FUCS) Bogotá Colombia
4 shared publicationsCamilo Montero
Renal Transplant Service, Clínica Universitaria Colombia Keralty, Bogota, Colombia
3 shared publications- Carlos Rosselli
Fundación Universitaria Ciencias de la Salud, Bogotá, Colombia; Hospital de San José, Bogotá, Colombia
3 shared publications Jonth Flechas
Nephrology Service, San José Hospital, Bogotá, Colombia
3 shared publications
Latest Publications
- Open Access
- 20 November 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
A retrospective study of the incidence of cancer and associated risk factors in kidney transplant patients in a Latin American population between 2007 and 2022
Background: Kidney transplantation is the ideal treatment for patients with end-stage renal disease. However, this population has a higher risk of cancer. This highlights the importance of early screening to improve outcomes in the detection of neoplasms, associated risk factors, and prompt treatment in this population. Objectives: The objective of this study is to determine the incidence and risk factors associated with post-transplant cancer. Methods: This was a historical analytical cohort observational study that evaluated the incidence of cancer and associated risk factors in kidney transplant recipients in the Clínica Universitaria Colombia program between 2007 and 2022. Result: A total of 555 patients were included, with a predominance of males (61.1%). An incidence of posttransplant cancer was documented in n = 79 (14%) patients at a follow-up of 84.7 months, with skin neoplasms in n = 33 (41.7%) of cases, followed by solid organ neoplasms n = 31 (39.2%). Associated risk factors identified were age at the time of transplantation being statistically significant (Hazard ratio (HR): 1.04; 95% confidence interval (CI): 1.02–1.06), a history of cancer prior to kidney transplantation (HR: 3.62; 95% CI: 1.46–8.99), and diabetes mellitus (HR: 2.08; 95% CI: 1.24–3.49). A statistically significant relationship was documented as a protective factor for mammalian Target of Rapamicyn (mTOR) inhibitors and solid organ neoplasms with relative risk (RR) 0.414 (95% CI: 0.19–0.88). No increase of posttransplant lymphoproliferative disorder (PTLD) was found with co-stimulation signal inhibitor-based therapy. Conclusions: In a Latin American kidney transplant cohort the incidence of post-transplant malignancy was found to be 14% in a median follow-up of 7 years. This study found that risk factors include age, history of cancer prior to transplantation, and diabetes mellitus. Use of mTOR pathway inhibitors was associated with a reduced risk of solid organ neoplasms. No increase in the frequency of PTLD was found in patients receiving costimulation signal inhibitors.
- 20 November 2025
- Published by SAGE Publications in Sage Open Medicine
- Vol. 13
Open AccessA retrospective study of the incidence of cancer and associated risk factors in kidney transplant patients in a Latin American population between 2007 and 2022
Background: Kidney transplantation is the ideal treatment for patients with end-stage renal disease. However, this population has a higher risk of cancer. This highlights the importance of early screening to improve outcomes in the detection of neoplasms, associated risk factors, and prompt treatment in this population. Objectives: The objective of this study is to determine the incidence and risk factors associated with post-transplant cancer. Methods: This was a historical analytical cohort observational study that evaluated the incidence of cancer and associated risk factors in kidney transplant recipients in the Clínica Universitaria Colombia program between 2007 and 2022. Result: A total of 555 patients were included, with a predominance of males (61.1%). An incidence of posttransplant cancer was documented in n = 79 (14%) patients at a follow-up of 84.7 months, with skin neoplasms in n = 33 (41.7%) of cases, followed by solid organ neoplasms n = 31 (39.2%). Associated risk factors identified were age at the time of transplantation being statistically significant (Hazard ratio (HR): 1.04; 95% confidence interval (CI): 1.02–1.06), a history of cancer prior to kidney transplantation (HR: 3.62; 95% CI: 1.46–8.99), and diabetes mellitus (HR: 2.08; 95% CI: 1.24–3.49). A statistically significant relationship was documented as a protective factor for mammalian Target of Rapamicyn (mTOR) inhibitors and solid organ neoplasms with relative risk (RR) 0.414 (95% CI: 0.19–0.88). No increase of posttransplant lymphoproliferative disorder (PTLD) was found with co-stimulation signal inhibitor-based therapy. Conclusions: In a Latin American kidney transplant cohort the incidence of post-transplant malignancy was found to be 14% in a median follow-up of 7 years. This study found that risk factors include age, history of cancer prior to transplantation, and diabetes mellitus. Use of mTOR pathway inhibitors was associated with a reduced risk of solid organ neoplasms. No increase in the frequency of PTLD was found in patients receiving costimulation signal inhibitors.
- Open Access
- 3 April 2025
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 12 (2)
Monitoreo continuo de glucosa en pacientes diabéticos con enfermedad renal crónica, en manejo con insulina y diálisis peritoneal
Contexto: los pacientes con diabetes mellitus (DM) y enfermedad renal diabética (ERD) enfrentan una mayor morbimortalidad por enfermedades cardiovasculares. El control glucémico es un reto debido a las múltiples variaciones metabólicas durante la terapia dialítica y una monitorización cuidadosa es clave para prevenir complicaciones en esta población. Objetivo: el objetivo de este estudio fue describir el comportamiento de la glucemia, determinado por el monitoreo continuo de glucosa (MCG) en la población renal diabética en terapia de diálisis peritoneal (DP), describir las variables del monitoreo continuo de glucosa y su correlación con la modalidad de diálisis peritoneal, con las concentraciones de diálisis a base de glucosa; así como con las variables analíticas y nutricionales. Metodología: estudio de cohorte prospectivo. Se incluyeron pacientes con DM tipo 1 y 2 con ERD terminal en DP. Resultados: se incluyeron 46 pacientes con enfermedad renal crónica (ERC) en DP, con una mediana de edad de 63 años (RIQ?=?54,3-69,8), de los cuales el 65?% fueron de sexo masculino. El 93?% tenía DM tipo 2, con una mediana de tiempo de diagnóstico de 20 años; el 76,1?% se encontraban bajo terapia de diálisis peritoneal ambulatoria continua (CAPD, según sus siglas en inglés) y el 23,9?% estaba bajo terapia de diálisis peritoneal automatizada (APD, según sus siglas en inglés). La mediana de hemoglobina glicada (HbA1C) fue del 7,5?% (RIQ?=?7-8.3) y la mediana del indicador de control de glucosa (GMI, según sus siglas en inglés) fue del 7,2?% (RIQ?=?6,7-7,6). La mediana de tiempo en rango (TIR, según sus siglas en inglés), tiempo sobre rango (TSR) y tiempo por debajo de rango (TBR, según sus siglas en inglés) fue del 60,5?%, 34,0?% y 0,5?%, respectivamente. Conclusiones: se observó una tendencia a la hiperglucemia en pacientes sometidos a DP, principalmente en aquellos con soluciones de diálisis con mayor concentración de glucosa.
- 3 April 2025
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 12 (2)
Open AccessMonitoreo continuo de glucosa en pacientes diabéticos con enfermedad renal crónica, en manejo con insulina y diálisis peritoneal
Contexto: los pacientes con diabetes mellitus (DM) y enfermedad renal diabética (ERD) enfrentan una mayor morbimortalidad por enfermedades cardiovasculares. El control glucémico es un reto debido a las múltiples variaciones metabólicas durante la terapia dialítica y una monitorización cuidadosa es clave para prevenir complicaciones en esta población. Objetivo: el objetivo de este estudio fue describir el comportamiento de la glucemia, determinado por el monitoreo continuo de glucosa (MCG) en la población renal diabética en terapia de diálisis peritoneal (DP), describir las variables del monitoreo continuo de glucosa y su correlación con la modalidad de diálisis peritoneal, con las concentraciones de diálisis a base de glucosa; así como con las variables analíticas y nutricionales. Metodología: estudio de cohorte prospectivo. Se incluyeron pacientes con DM tipo 1 y 2 con ERD terminal en DP. Resultados: se incluyeron 46 pacientes con enfermedad renal crónica (ERC) en DP, con una mediana de edad de 63 años (RIQ?=?54,3-69,8), de los cuales el 65?% fueron de sexo masculino. El 93?% tenía DM tipo 2, con una mediana de tiempo de diagnóstico de 20 años; el 76,1?% se encontraban bajo terapia de diálisis peritoneal ambulatoria continua (CAPD, según sus siglas en inglés) y el 23,9?% estaba bajo terapia de diálisis peritoneal automatizada (APD, según sus siglas en inglés). La mediana de hemoglobina glicada (HbA1C) fue del 7,5?% (RIQ?=?7-8.3) y la mediana del indicador de control de glucosa (GMI, según sus siglas en inglés) fue del 7,2?% (RIQ?=?6,7-7,6). La mediana de tiempo en rango (TIR, según sus siglas en inglés), tiempo sobre rango (TSR) y tiempo por debajo de rango (TBR, según sus siglas en inglés) fue del 60,5?%, 34,0?% y 0,5?%, respectivamente. Conclusiones: se observó una tendencia a la hiperglucemia en pacientes sometidos a DP, principalmente en aquellos con soluciones de diálisis con mayor concentración de glucosa.
- Open Access
- 1 December 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (4) , e20240101
Kidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature.
- 1 December 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (4) , e20240101
Open AccessKidney effects of Glucagon-Like Peptide 1 (GLP1): from molecular foundations to a pharmacophysiological perspective
GLP1 receptor agonists (GLP1-RAs) are drugs that mimic the effects of the incretin hormone GLP1 and were initially introduced in medicine for the treatment of diabetes in 2005 and for obesity in 2014. Over time, data from secondary and exploratory objectives of large randomized controlled-trials suggested that GLP1-RAs could also exert renal action by slowing the progression of kidney disease in patients with and without diabetes. Based on this rationale, the Flow study (1 mg semaglutide vs placebo) was designed and recruitment began in 2019 until May 2021. The recently published results confirmed the effect of semaglutide in reducing the composite renal outcome. However, similar to SGLT2 inhibitors, the potential mechanisms behind the renal effects of GLP1-RAs still need to be elucidated. The aim of this review is to address the different physiological mechanisms of GLP1-RAs at the renal level, using evidence from experimental studies and current scientific literature.
- Open Access
- 1 December 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (4) , e20240101
Efeitos renais do Peptídeo 1 Semelhante ao Glucagon (GLP1): das bases moleculares a uma perspectiva farmacofisiológica
Os agonistas do receptor de GLP1 (GLP1-RAs) são medicamentos que imitam os efeitos do hormônio incretínico GLP1. Eles foram inicialmente introduzidos na medicina para o tratamento do diabetes em 2005 e para a obesidade em 2014. Com o passar do tempo, dados provenientes de objetivos secundários e exploratórios de amplos ensaios clínicos randomizados sugeriram que os GLP1-RAs também poderiam exercer ação renal ao retardar a progressão da doença renal em pacientes com e sem diabetes. Com base nesse raciocínio, o estudo Flow (semaglutida 1 mg vs. placebo) foi desenhado e o recrutamento começou em 2019, estendendo-se até maio de 2021. Os resultados publicados recentemente confirmaram o efeito da semaglutida na redução do desfecho renal composto. No entanto, assim como os inibidores do SGLT2, os mecanismos potenciais por trás dos efeitos renais dos GLP1-RAs ainda precisam ser elucidados. O objetivo desta revisão é abordar os diferentes mecanismos fisiológicos dos GLP1-RAs em nível renal, utilizando evidências de estudos experimentais e da literatura científica atual.
- 1 December 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 46 (4) , e20240101
Open AccessEfeitos renais do Peptídeo 1 Semelhante ao Glucagon (GLP1): das bases moleculares a uma perspectiva farmacofisiológica
Os agonistas do receptor de GLP1 (GLP1-RAs) são medicamentos que imitam os efeitos do hormônio incretínico GLP1. Eles foram inicialmente introduzidos na medicina para o tratamento do diabetes em 2005 e para a obesidade em 2014. Com o passar do tempo, dados provenientes de objetivos secundários e exploratórios de amplos ensaios clínicos randomizados sugeriram que os GLP1-RAs também poderiam exercer ação renal ao retardar a progressão da doença renal em pacientes com e sem diabetes. Com base nesse raciocínio, o estudo Flow (semaglutida 1 mg vs. placebo) foi desenhado e o recrutamento começou em 2019, estendendo-se até maio de 2021. Os resultados publicados recentemente confirmaram o efeito da semaglutida na redução do desfecho renal composto. No entanto, assim como os inibidores do SGLT2, os mecanismos potenciais por trás dos efeitos renais dos GLP1-RAs ainda precisam ser elucidados. O objetivo desta revisão é abordar os diferentes mecanismos fisiológicos dos GLP1-RAs em nível renal, utilizando evidências de estudos experimentais e da literatura científica atual.
- Open Access
- 29 May 2024
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 11 (2)
Lupus eritematoso sistémico de inicio tardío con presentación de glomerulonefritis rápidamente progresiva: Reporte de caso.
Introducción: el lupus eritematoso sistémico (LES) es una enfermedad autoinmunitaria, con compromiso multisistémico que afecta principalmente a mujeres jóvenes; no obstante, existe un fenotipo distinto de inicio tardío del LES, generalmente definido en la literatura y de aparición después de los 50 años, con un curso más leve, grupo en el que es atípico el compromiso renal, empeorando este los desenlaces clínicos. Objetivo: es importante conocer esta presentación atípica de la enfermedad para incluirla como un diagnóstico diferencial en los pacientes y realizar un diagnóstico oportuno que evite desenlaces clínicos adversos. Presentación del caso: se presenta el caso de un hombre de 57 años que consultó con cuadro de deterioro de su clase funcional asociado a edemas, con antecedente reciente de trombosis venosa profunda e hipertensión arterial, se documentó en los análisis de laboratorio elevación de azoados, acidosis metabólica moderada, proteinuria en rango nefrótico con hematuria glomerular, bajos niveles de albúmina en suero y ANA (anticuerpos antinucleares) positivos. Discusión y conclusión: los resultados de la biopsia renal indicaron glomerulonefritis membranoproliferativa con depósitos de complejos inmunes subendoteliales y patrón de inmunofluorescencia “full house”. Se consideró glomerulonefritis rápidamente progresiva (GNRP) como manifestación inicial de un LES de inicio tardío, requiriendo terapia de reemplazo renal, recibió tratamiento con esteroide endovenoso a dosis altas y ciclofosfamida, sin deterioro mayor de su estado clínico o de la función renal, sin embargo, el paciente continuó con requerimiento de hemodiálisis.
- 29 May 2024
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 11 (2)
Open AccessLupus eritematoso sistémico de inicio tardío con presentación de glomerulonefritis rápidamente progresiva: Reporte de caso.
Introducción: el lupus eritematoso sistémico (LES) es una enfermedad autoinmunitaria, con compromiso multisistémico que afecta principalmente a mujeres jóvenes; no obstante, existe un fenotipo distinto de inicio tardío del LES, generalmente definido en la literatura y de aparición después de los 50 años, con un curso más leve, grupo en el que es atípico el compromiso renal, empeorando este los desenlaces clínicos. Objetivo: es importante conocer esta presentación atípica de la enfermedad para incluirla como un diagnóstico diferencial en los pacientes y realizar un diagnóstico oportuno que evite desenlaces clínicos adversos. Presentación del caso: se presenta el caso de un hombre de 57 años que consultó con cuadro de deterioro de su clase funcional asociado a edemas, con antecedente reciente de trombosis venosa profunda e hipertensión arterial, se documentó en los análisis de laboratorio elevación de azoados, acidosis metabólica moderada, proteinuria en rango nefrótico con hematuria glomerular, bajos niveles de albúmina en suero y ANA (anticuerpos antinucleares) positivos. Discusión y conclusión: los resultados de la biopsia renal indicaron glomerulonefritis membranoproliferativa con depósitos de complejos inmunes subendoteliales y patrón de inmunofluorescencia “full house”. Se consideró glomerulonefritis rápidamente progresiva (GNRP) como manifestación inicial de un LES de inicio tardío, requiriendo terapia de reemplazo renal, recibió tratamiento con esteroide endovenoso a dosis altas y ciclofosfamida, sin deterioro mayor de su estado clínico o de la función renal, sin embargo, el paciente continuó con requerimiento de hemodiálisis.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Sage Open Medicine
- Vol. 12
Renal function outcomes in living kidney donors in a transplant center in Colombia
Introduction: Living kidney donation is currently low in Colombia, and this is associated with the lack of knowledge of the risks and renal function outcomes of potential donors; there are no studies that evaluate these outcomes. The objective of this study is to evaluate the outcomes of renal function, the incidence of metabolic diseases, arterial hypertension, as well as the finding of albuminuria and/or proteinuria in living kidney donors with a 2-year follow-up post donation. Methods: Observational study in living kidney donor patients, in which renal function outcomes were evaluated between the predonation period and up to 24 months postdonation. Results: Ninety-one patients were included, with a median predonation glomerular filtration rate of 98 ml/min/1.73 m2, interquartile range (90.5–109), and 24-month postdonation of 66.3 ml/min/1.73 m2 interquartile range (57.9–75). A total of 60.26% of the population was in stage 2 at the end of follow-up and no patient had a glomerular filtration rate less than 30 ml/min/1.73 m2 or required renal support therapy. Conclusion: A living donor evaluation process based on risk factor stratification and adequate assessment of renal function was found to generate safe renal function outcomes both in the perioperative period and in medium- and long-term follow-up.
- 1 January 2024
- Published by SAGE Publications in Sage Open Medicine
- Vol. 12
Open AccessRenal function outcomes in living kidney donors in a transplant center in Colombia
Introduction: Living kidney donation is currently low in Colombia, and this is associated with the lack of knowledge of the risks and renal function outcomes of potential donors; there are no studies that evaluate these outcomes. The objective of this study is to evaluate the outcomes of renal function, the incidence of metabolic diseases, arterial hypertension, as well as the finding of albuminuria and/or proteinuria in living kidney donors with a 2-year follow-up post donation. Methods: Observational study in living kidney donor patients, in which renal function outcomes were evaluated between the predonation period and up to 24 months postdonation. Results: Ninety-one patients were included, with a median predonation glomerular filtration rate of 98 ml/min/1.73 m2, interquartile range (90.5–109), and 24-month postdonation of 66.3 ml/min/1.73 m2 interquartile range (57.9–75). A total of 60.26% of the population was in stage 2 at the end of follow-up and no patient had a glomerular filtration rate less than 30 ml/min/1.73 m2 or required renal support therapy. Conclusion: A living donor evaluation process based on risk factor stratification and adequate assessment of renal function was found to generate safe renal function outcomes both in the perioperative period and in medium- and long-term follow-up.
- 15 December 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (3) , 228-233
Incidence of major cardiovascular events at 1, 2, and 5 years and mortality in incident patients on peritoneal dialysis regarding their nutritional status by bioimpedanciometry: A multicenter study in Colombia
Background: The nutritional status of incident patients on peritoneal dialysis (PD) has been associated with survival outcomes. Bioimpedanciometry (BCM) enables to establish a nutritional diagnosis, the volume status, and correlates these findings with survival.Methods: This study used a retrospective multicenter historical cohort.Results: In this study, which included 420 incident patients on peritoneal dialysis with a 5‐year follow‐up, a cumulative incidence of major adverse cardiovascular events (MACE) of 28.8% was found, being higher in the diabetic population at 36.8%. In regard to the nutritional status in this population, it was found that approximately 44% had altered nutritional status; 34% were found to be in sarcopenia; 6.7% sarcopenic obesity; and 2.8% in obesity (p < 0.001). In the survival analysis, a lower probability of survival was found in patients with overhydration (OH) greater than 3 L (p < 0.001) and in patients with altered nutritional status due to sarcopenia, sarcopenic obesity, and obesity (p 0.016). According to survival in the subgroup of the diabetic population, a lower probability of survival was found in this group of patients (p: 0.011). The overall mortality of the study population was 18%, being higher in the first 2 years, with the most important causes of mortality being cardiovascular. Of the deceased population, 51% were diabetic patients (p: 0.012).Conclusion: In incident patients on peritoneal dialysis, sarcopenic obesity, sarcopenia, overhydration status determined by BCM, and having a diagnosis of diabetes are related to a lower probability of survival; MACE outcomes are more frequent in the diabetic population.
- 15 December 2023
- Published by Wiley in Seminars in Dialysis
- Vol. 37 (3) , 228-233
Incidence of major cardiovascular events at 1, 2, and 5 years and mortality in incident patients on peritoneal dialysis regarding their nutritional status by bioimpedanciometry: A multicenter study in Colombia
Background: The nutritional status of incident patients on peritoneal dialysis (PD) has been associated with survival outcomes. Bioimpedanciometry (BCM) enables to establish a nutritional diagnosis, the volume status, and correlates these findings with survival.Methods: This study used a retrospective multicenter historical cohort.Results: In this study, which included 420 incident patients on peritoneal dialysis with a 5‐year follow‐up, a cumulative incidence of major adverse cardiovascular events (MACE) of 28.8% was found, being higher in the diabetic population at 36.8%. In regard to the nutritional status in this population, it was found that approximately 44% had altered nutritional status; 34% were found to be in sarcopenia; 6.7% sarcopenic obesity; and 2.8% in obesity (p < 0.001). In the survival analysis, a lower probability of survival was found in patients with overhydration (OH) greater than 3 L (p < 0.001) and in patients with altered nutritional status due to sarcopenia, sarcopenic obesity, and obesity (p 0.016). According to survival in the subgroup of the diabetic population, a lower probability of survival was found in this group of patients (p: 0.011). The overall mortality of the study population was 18%, being higher in the first 2 years, with the most important causes of mortality being cardiovascular. Of the deceased population, 51% were diabetic patients (p: 0.012).Conclusion: In incident patients on peritoneal dialysis, sarcopenic obesity, sarcopenia, overhydration status determined by BCM, and having a diagnosis of diabetes are related to a lower probability of survival; MACE outcomes are more frequent in the diabetic population.
- 19 August 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (7) , 2159-2162
Glomerular disease after renal transplantation: a multi-center surveillance biopsy study in a Latin American population
- 19 August 2023
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 36 (7) , 2159-2162
Glomerular disease after renal transplantation: a multi-center surveillance biopsy study in a Latin American population
- Open Access
- 24 February 2023
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 10 (2)
Hipercalcemia asociada a hiperparatiroidismo primario: enfoque y manejo a partir de un caso clínico
Background: Calcium is the most abundant electrolyte in the human body, hypercalcemia is a common disorder usually caused by primary hyperparathyroidism or malignancy. A proportion of cases presenting as an emergency, leading to significant mortality. The management of hypercalcemia depends on the presentation and underlying cause. Purpose: to present an unusual case of clinical presentation of hypercalcemia associated with primary hyperparathyroidism, as well as to give a brief review about the approach and management of this pathology. Case presentation: A 32-year-old female patient, with a history of unresected parathyroid adenoma and pancreatitis, attended for 3 days of abdominal pain, moderate intensity, accompanied by emetic episodes of food content, initial paraclinical findings showed severe hypercalcemia, electrocardiogram with block grade I atrioventricular, arterial gases with acute respiratory alkalosis and hyperlactatemia. CT of the abdomen with brown tumors. She was admitted to the ICU for administration of intravenous fluids, loop diuretics, and cinacalcet without showing any improvement, so hemodialysis therapy was indicated. Discussion and conclusion: hypercalcemia is a frequent finding. Primary hyperparathyroidism and malignancy are the two most common causes of elevated serum calcium levels, together accounting for about 90% of all cases. Serum values vary between total calcium 8.5 and 10.5 mg/dl and ionic 1.16-1.31. Serum Ca 2+ concentration is closely related by the actions of parathyroid hormone and calcitriol. Primary hyperparathyroidism occurs as a result of adenomas, hyperplasias, or carcinoma. The clinical manifestations and severity will be correlated with the duration of the disease, calcium and PTH levels. Within the treatment, this will be guided by its cause, however, it is possible to classify it into urgent and non-urgent treatment. The approach to severe acute hypercalcemia is a diagnostic challenge given the multiple causes that can lead to this hydroelectrolyte disorder and the rapid establishment of treatment that is required when it is detected. Introducción: el calcio es el electrolito más abundante del cuerpo humano y la hipercalcemia es el trastorno común causado normalmente por el hiperparatiroidismo primario o malignidad, su manejo depende de la presentación y causa subyacente. Además, una proporción de casos se presentan como una emergencia, lo que conlleva a una mortalidad significativa. Objetivo: mostrar un caso inusual de presentación clínica de hipercalcemia asociada a hiperparatiroidismo primario y, asimismo, dar una breve revisión acerca del enfoque y el manejo de esta patología. Presentación del caso: paciente femenina de 32 años, antecedente de adenoma paratiroideo no resecado y pancreatitis, asiste por tres días de dolor abdominal de tipo cólico y de moderada intensidad, acompañado de episodios eméticos de contenido alimentario, paraclínicos iniciales con hipercalcemia severa, electrocardiograma con bloqueo auriculoventricular grado I, gases arteriales con alcalosis respiratoria aguda e hiperlactatemia. También se le practicó un TAC de abdomen donde este apareció con tumores pardos. Se ingreso? a la UCI para la administración de líquidos endovenosos, diuréticos de asa y cinacalcet, pero no presentó mejoría, por lo que se indicó terapia de hemodiálisis. Discusión y conclusión: la hipercalcemia es un hallazgo frecuente. El hiperparatiroidismo primario y la neoplasia maligna son las dos causas más frecuentes de aumento de los niveles de calcio sérico y, en conjunto, representan alrededor del 90?% de todos los casos, donde los valores en suero varían entre el calcio total (8,5 y 10,5 mg/dl) y el iónico (1,16-1,31). La concentración sérica de Ca 2+ esta? estrechamente relacionada por las acciones de la hormona paratiroidea y el calcitriol, donde el hiperparatiroidismo primario ocurre como resultado de adenomas, hiperplasias y carcinoma. Las manifestaciones clínicas y la severidad van a estar correlacionadas con el tiempo de duración de la enfermedad, los niveles de calcio y de PTH. Dentro del tratamiento, este será guiado por su causa, sin embargo, es posible clasificarlo en tratamiento urgente y no urgente. Además, el enfoque de la hipercalcemia aguda severa es un reto diagnóstico dadas las múltiples causas que pueden llevar a este trastorno hidroelectrolítico y la rápida instauración de tratamiento que se requiere cuando es detectada.
- 24 February 2023
- Published by Asociacion Colombiana de Nefrologia e Hipertension Arterial in Revista Colombiana de Nefrología
- Vol. 10 (2)
Open AccessHipercalcemia asociada a hiperparatiroidismo primario: enfoque y manejo a partir de un caso clínico
Background: Calcium is the most abundant electrolyte in the human body, hypercalcemia is a common disorder usually caused by primary hyperparathyroidism or malignancy. A proportion of cases presenting as an emergency, leading to significant mortality. The management of hypercalcemia depends on the presentation and underlying cause. Purpose: to present an unusual case of clinical presentation of hypercalcemia associated with primary hyperparathyroidism, as well as to give a brief review about the approach and management of this pathology. Case presentation: A 32-year-old female patient, with a history of unresected parathyroid adenoma and pancreatitis, attended for 3 days of abdominal pain, moderate intensity, accompanied by emetic episodes of food content, initial paraclinical findings showed severe hypercalcemia, electrocardiogram with block grade I atrioventricular, arterial gases with acute respiratory alkalosis and hyperlactatemia. CT of the abdomen with brown tumors. She was admitted to the ICU for administration of intravenous fluids, loop diuretics, and cinacalcet without showing any improvement, so hemodialysis therapy was indicated. Discussion and conclusion: hypercalcemia is a frequent finding. Primary hyperparathyroidism and malignancy are the two most common causes of elevated serum calcium levels, together accounting for about 90% of all cases. Serum values vary between total calcium 8.5 and 10.5 mg/dl and ionic 1.16-1.31. Serum Ca 2+ concentration is closely related by the actions of parathyroid hormone and calcitriol. Primary hyperparathyroidism occurs as a result of adenomas, hyperplasias, or carcinoma. The clinical manifestations and severity will be correlated with the duration of the disease, calcium and PTH levels. Within the treatment, this will be guided by its cause, however, it is possible to classify it into urgent and non-urgent treatment. The approach to severe acute hypercalcemia is a diagnostic challenge given the multiple causes that can lead to this hydroelectrolyte disorder and the rapid establishment of treatment that is required when it is detected. Introducción: el calcio es el electrolito más abundante del cuerpo humano y la hipercalcemia es el trastorno común causado normalmente por el hiperparatiroidismo primario o malignidad, su manejo depende de la presentación y causa subyacente. Además, una proporción de casos se presentan como una emergencia, lo que conlleva a una mortalidad significativa. Objetivo: mostrar un caso inusual de presentación clínica de hipercalcemia asociada a hiperparatiroidismo primario y, asimismo, dar una breve revisión acerca del enfoque y el manejo de esta patología. Presentación del caso: paciente femenina de 32 años, antecedente de adenoma paratiroideo no resecado y pancreatitis, asiste por tres días de dolor abdominal de tipo cólico y de moderada intensidad, acompañado de episodios eméticos de contenido alimentario, paraclínicos iniciales con hipercalcemia severa, electrocardiograma con bloqueo auriculoventricular grado I, gases arteriales con alcalosis respiratoria aguda e hiperlactatemia. También se le practicó un TAC de abdomen donde este apareció con tumores pardos. Se ingreso? a la UCI para la administración de líquidos endovenosos, diuréticos de asa y cinacalcet, pero no presentó mejoría, por lo que se indicó terapia de hemodiálisis. Discusión y conclusión: la hipercalcemia es un hallazgo frecuente. El hiperparatiroidismo primario y la neoplasia maligna son las dos causas más frecuentes de aumento de los niveles de calcio sérico y, en conjunto, representan alrededor del 90?% de todos los casos, donde los valores en suero varían entre el calcio total (8,5 y 10,5 mg/dl) y el iónico (1,16-1,31). La concentración sérica de Ca 2+ esta? estrechamente relacionada por las acciones de la hormona paratiroidea y el calcitriol, donde el hiperparatiroidismo primario ocurre como resultado de adenomas, hiperplasias y carcinoma. Las manifestaciones clínicas y la severidad van a estar correlacionadas con el tiempo de duración de la enfermedad, los niveles de calcio y de PTH. Dentro del tratamiento, este será guiado por su causa, sin embargo, es posible clasificarlo en tratamiento urgente y no urgente. Además, el enfoque de la hipercalcemia aguda severa es un reto diagnóstico dadas las múltiples causas que pueden llevar a este trastorno hidroelectrolítico y la rápida instauración de tratamiento que se requiere cuando es detectada.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
Response of antibody titers to SARS-CoV-2 vaccination and clinical outcomes during the predominance of the Omicron variant in Colombia
Introduction: The response to vaccination against the virus that causes severe acute respiratory infection syndrome coronavirus 2 is lower in renal transplant recipients than in the general population. The data obtained from Latin America showed reduced immunogenicity under inactivated virus vaccination schedules and messenger ribonucleic acid platforms. Methods: A retrospective cohort study including renal transplant recipients from Colombia with a two-dose vaccination schedule against severe acute respiratory infection syndrome coronavirus 2 with Pfizer, AstraZeneca, Moderna, Jansen, and Sinovac vaccines between March 1, 2021 and December 1, 2021, was carried out with a follow-up period to evaluate outcomes until May 2022. The outcomes correspond to the titers of immunoglobulin G antibodies against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike and a composite outcome of mortality, general, and intensive care unit hospitalization. Results: In total, 215 renal transplant recipients with two doses of vaccination for severe acute respiratory infection syndrome coronavirus 2 during the predominance of the Omicron variant in Colombia were included, with the measurement of immunoglobulin G antibody titers against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike at 8 weeks of vaccination. The mean age was 52.1 years, and the standard deviation was ± 14.2; severe acute respiratory infection syndrome coronavirus 2 infection occurred in 20% of the population, of which 23.26% required hospitalization, 13.95% were under intensive care unit management, and four cases of mortality (9.3%) were reported. Of the total population, 52.5% had antibody titers higher than 0.8 IU/mL (median 0.77 IU/mL, interquartile range 0.4–131). Patients with severe acute respiratory infection syndrome coronavirus 2 infection had a median antibody titer of 0.4 IU/mL (interquartile range 0.4–3.45), and those without infection had a median antibody titer of 1.8 IU/mL (interquartile range 0.4–202) ( p = 0.015). Conclusion: Anti-severe acute respiratory infection syndrome coronavirus 2 antibody titers with a cutoff point less than 0.8 IU/mL are associated with increased risk of severe acute respiratory infection syndrome coronavirus 2 infection.
- 1 January 2023
- Published by SAGE Publications in Sage Open Medicine
- Vol. 11
Open AccessResponse of antibody titers to SARS-CoV-2 vaccination and clinical outcomes during the predominance of the Omicron variant in Colombia
Introduction: The response to vaccination against the virus that causes severe acute respiratory infection syndrome coronavirus 2 is lower in renal transplant recipients than in the general population. The data obtained from Latin America showed reduced immunogenicity under inactivated virus vaccination schedules and messenger ribonucleic acid platforms. Methods: A retrospective cohort study including renal transplant recipients from Colombia with a two-dose vaccination schedule against severe acute respiratory infection syndrome coronavirus 2 with Pfizer, AstraZeneca, Moderna, Jansen, and Sinovac vaccines between March 1, 2021 and December 1, 2021, was carried out with a follow-up period to evaluate outcomes until May 2022. The outcomes correspond to the titers of immunoglobulin G antibodies against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike and a composite outcome of mortality, general, and intensive care unit hospitalization. Results: In total, 215 renal transplant recipients with two doses of vaccination for severe acute respiratory infection syndrome coronavirus 2 during the predominance of the Omicron variant in Colombia were included, with the measurement of immunoglobulin G antibody titers against the receptor binding domain of the severe acute respiratory infection syndrome coronavirus 2 spike at 8 weeks of vaccination. The mean age was 52.1 years, and the standard deviation was ± 14.2; severe acute respiratory infection syndrome coronavirus 2 infection occurred in 20% of the population, of which 23.26% required hospitalization, 13.95% were under intensive care unit management, and four cases of mortality (9.3%) were reported. Of the total population, 52.5% had antibody titers higher than 0.8 IU/mL (median 0.77 IU/mL, interquartile range 0.4–131). Patients with severe acute respiratory infection syndrome coronavirus 2 infection had a median antibody titer of 0.4 IU/mL (interquartile range 0.4–3.45), and those without infection had a median antibody titer of 1.8 IU/mL (interquartile range 0.4–202) ( p = 0.015). Conclusion: Anti-severe acute respiratory infection syndrome coronavirus 2 antibody titers with a cutoff point less than 0.8 IU/mL are associated with increased risk of severe acute respiratory infection syndrome coronavirus 2 infection.